A systematic multi-omics analysis pooling 22 transcriptomic, 6 proteomic, and 5 metabolomic datasets from metabolic bariatric surgery (MBS) patients identified sustained suppression of oncogenic signaling across adipose, skeletal muscle, and gastrointestinal tissues. Key cancer-associated pathways — including molecular mechanisms of cancer and metastasis-related signaling — were consistently downregulated post-operatively. Simultaneously, proteomic data showed early suppression of inflammatory and acute-phase proteins, progressive dampening of complement and coagulation cascades, and upregulation of sex hormone-binding globulin. Metabolomics revealed broad shifts in amino acid, bile acid, and lipid metabolism. Consistently regulated molecular markers across datasets included CCL2, EGFL6, and S100A8.
This analysis adds mechanistic depth to the already-established epidemiological observation that bariatric surgery reduces cancer incidence by roughly 30–40% in cohort studies. By triangulating three independent omics layers, the findings are more credible than any single-modality study could produce. The hormonal rebalancing — particularly SHBG upregulation — is especially relevant for obesity-linked hormone-sensitive cancers such as breast and endometrial. However, important limitations apply: this is a systematic analysis of pre-existing datasets rather than a prospectively designed trial, sample sizes within individual studies are modest, and causal inference remains constrained. Whether these molecular changes mediate cancer risk reduction or are simply correlates of weight loss and metabolic improvement cannot yet be determined. Still, the identification of CCL2, EGFL6, and S100A8 as cross-omics biomarkers provides tractable targets for future mechanistic and translational research. Incremental but well-executed.